文献速递免疫规划卫生政策与健康促进慢病防控与筛查

芬兰≥20岁成人带状疱疹发病率(2015至2023年):一项基于人群的登记研究

Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study.
PubMed 文献 · Euro Surveill · 2025-01-01

该研究链接芬兰多个全国性健康登记数据,估算2015至2023年≥20岁成人带状疱疹年龄别年发病率,共识别220,693例病例;2023年登记覆盖最佳时,年龄别年发病率随年龄增长从3.8至12.2不等,女性高于男性,≥85岁居家无组织照护的老年人中最高;2023年累积发病率数据显示,到85岁时终生罹患带状疱疹的风险为42%,使用居家无组织照护老年人的发病率计算则高达46%。结论指出带状疱疹发病率因性别和年龄组而异,在机构和组织照护环境中似乎存在漏报;尽管国家专家组和国家疫苗接种咨询委员会提出了有利建议,芬兰目前尚无关于带状疱疹疫苗接种的官方决定。

要点

  • 2015至2023年芬兰≥20岁成人共识别220,693例带状疱疹病例。
  • 2023年年龄别年发病率随年龄增长从3.8至12.2不等,女性高于男性。
  • 2023年数据显示85岁时终生罹患带状疱疹风险为42%,居家无组织照护老年人为46%。

核心结论

  • 带状疱疹发病率因性别和年龄组而异,在机构和组织照护环境中似乎存在漏报。
  • 尽管国家专家组和国家疫苗接种咨询委员会提出了有利建议,芬兰目前尚无关于带状疱疹疫苗接种的官方决定。

研究设计与样本

  • 全国性研究,链接多个基于人群的登记数据,覆盖2015至2023年芬兰全部人口,数据集包含芬兰几乎所有医疗保健提供者的记录。
  • 病例定义基于ICD-10编码B02和G53.0以及ICPC-2编码S70,并补充处方抗病毒药物购买信息。

主要发现

  • 2015至2023年共识别220,693例≥20岁成人带状疱疹病例。
  • 2023年登记覆盖最佳时,全人群年龄别年发病率从3.8至12.2不等,随年龄增长而升高。
  • 女性发病率高于男性,≥85岁居家无组织照护的老年人中发病率最高。
  • 2023年累积发病率数据显示,到85岁时终生罹患带状疱疹的风险为42%,使用居家无组织照护老年人的发病率计算则高达46%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出在机构和组织照护环境中似乎存在漏报。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDHerpes zoster, also known as shingles, is a painful skin condition caused by varicella zoster virus. Information is lacking on incidence of herpes zoster in Finland.AIMTo estimate age-specific annual incidence of herpes zoster over 9 years with data from several nationwide health registers.METHODSIn a nationwide study, we compiled a dataset encompassing the entire Finnish population by linking data from multiple population-based registers for 2015-23. The dataset includes records from nearly all healthcare providers in Finland. Case definitions were based on ICD-10 codes B02 and G53.0, and ICPC-2 code S70. The dataset was supplemented with information on the purchase of prescribed antiviral medication.RESULTSIn total, 220,693 herpes zoster cases were identified during 2015-23 among adults aged ≥ 20 years. In 2023, when register coverage was best, age-specific annual incidence rates for the entire population varied from 3.8 to 12.2, increasing with age. Incidence was higher among females than males, and highest among elderly aged ≥ 85 years living at home without organised care. Cumulative incidence data from 2023 revealed that lifetime risk of developing herpes zoster by age 85 was 42%, and as high as 46% using the incidence among elderly living at home without organised care.CONCLUSIONHerpes zoster incidence varied by sex and age group, and appeared to be under-reported in institutional and organised care settings. Currently, there is no official decision on herpes zoster vaccination in Finland, despite favourable recommendations from the national expert group and the National Advisory Committee on Vaccination.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Juutinen A, Salo H, Lehtonen T, et al. Herpes zoster incidence in adults aged ≥ 20 years in Finland, 2015 to 2023: a population-based register study. Euro Surveill. 2025. PMID: 40910227. doi:10.2807/1560-7917.ES.2025.30.35.2500077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。